Publications (26)140.23 Total impact
-
Article: Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis.
[show abstract] [hide abstract]
ABSTRACT: To study the prevalence of ocular manifestations in African American and Caucasian patients with biopsy-proven sarcoidosis at the initial ophthalmic examination and to determine the relationship between angiotensin-converting enzyme (ACE) levels, chest x-ray findings, and ocular signs of sarcoidosis. Retrospective, cross-sectional, observational study. Eighty-one consecutive patients with biopsy-proven sarcoidosis seen at the Doheny Eye Institute from January 1989 through April 2005. Medical records were reviewed to obtain demographic data, biopsy site, initial ocular findings, pulmonary symptoms, and results of serum ACE levels and chest x-rays. Associations between ACE level/chest x-ray stages and ocular manifestations related to sarcoidosis were obtained from these data. Ocular manifestations related to sarcoidosis. Of the 81 patients, 35 were Caucasian; 29 were African American; and the remaining 17 were Hispanic, Asian Indian, and other races. Female patients were older than males (P = 0.05). Sixty-five (80%) of the 81 patients had ocular manifestations related to sarcoidosis. Thirty-three patients (40.7%) had uveitis, 12 (14.8%) had adnexal granulomas, and 25 (30.8%) had keratoconjunctivitis sicca. Of the 33 patients with uveitis, 22 presented with nongranulomatous inflammation. There was no significant association between ocular manifestations related to sarcoidosis and serum ACE levels (P = 0.43) or chest x-ray stage (P>0.99). Of the 29 African American patients, 26 (89.7%) had ocular manifestations related to sarcoidosis, compared with 24 (68.6%) of the 35 Caucasians (P = 0.12). The African American patients were younger (mean age, 44.4 years) than the Caucasian patients (mean age, 52.0) (P = 0.003) and had higher mean ACE levels (P = 0.003). A significantly high proportion of African American males presented with uveitis (P = 0.005), and a significantly high proportion of African American females presented with adnexal granulomas (P = 0.05). The present study reveals that patients with sarcoidosis can present initially with clinical features of nongranulomatous uveitis. Relative to Caucasians, African American patients with sarcoidosis tend to be younger when they first present to the ophthalmologist and to present with uveitis and/or adnexal granuloma. Serum ACE levels and chest x-ray stages may not help predict the occurrence of ocular changes in sarcoidosis.Ophthalmology 03/2007; 114(2):325-33. · 5.45 Impact Factor -
Article: One-year results of a pilot study using oral 13-cis retinoic acid as a treatment for subfoveal predominantly occult choroidal neovascularization in patients with age-related macular degeneration.
[show abstract] [hide abstract]
ABSTRACT: To evaluate the safety and evidence of efficacy for oral 13-cis retinoic acid as a treatment for patients with subfoveal occult choroidal neovascularization (CNV) due to age-related macular degeneration (ARMD). Patients with active, subfoveal occult CNV with no prior treatment of the subfoveal component were eligible for inclusion. Patients received 40 mg of 13-cis retinoic acid twice daily for 5 months, stopped treatment for 2 months, and then resumed treatment for 5 months. Patients were observed monthly with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA), clinical examination, fluorescein angiography, and laboratory testing. Eleven patients, aged 64 to 88 years, were enrolled and followed for 1 year. Initial VA ranged from 55 (20/40) to 5 (20/400) ETDRS letters (median 48 letters). Mild drug-related side effects (dry skin, chapped lips) occurred in all 11 patients. Three patients experienced more severe side effects (muscle aches, mood swings) and did not resume treatment after the drug holiday. Moderate VA loss occurred in 36% at both 6 and 12 months. Oral 13-cis retinoic acid is too toxic to be useful in patients with ARMD. Oral 13-cis retinoic acid did not improve vision although it may have slowed visual acuity loss in patients with ARMD with occult subfoveal CNV.Retina 04/2006; 26(3):314-21. · 2.81 Impact Factor -
Article: Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease.
[show abstract] [hide abstract]
ABSTRACT: To review the long-term outcome of photodynamic therapy (PDT) with verteporfin for inflammatory chorioretinal disease with subfoveal choroidal neovascularisation (CNV) over a 1-year period. Retrospective review of eyes with subfoveal CNV for associated choroiditis that were treated with PDT using verteporfin over a 1-year period. visual acuity. Five eyes in 4 patients, with diagnoses including serpiginous choroiditis (2), ocular histoplasmosis syndrome (OHS, 1), and punctate inner choroidopathy (PIC, 2) underwent standard treatment procedure for PDT with verteporfin. Visual acuity, fluorescein angiography and treatment parameters were reviewed. Follow-up ranged from 12 months to 36 months (median, 36 months). Pre-PDT visual acuities ranged from 20/60 to 20/400 (median, 20/200). Post-PDT visual acuities ranged from 20/30 to 20/400 at 1 year (median, 20/300). Visual acuity was stabilised (within 1 line) or improved (greater than 1 line) in 3 eyes at 1 year and 4 of the 5 eyes at last follow-up. PDT for subfoveal CNV may stabilise, but rarely improves, visual acuity in eyes with choroidal neovascularisation secondary to inflammatory chorioretinal disease.Annals of the Academy of Medicine, Singapore 04/2006; 35(3):198-202. · 1.25 Impact Factor -
Article: Long-term study of intraocular pressure changes in patients with human immunodeficiency virus treated with highly active antiretroviral therapy.
[show abstract] [hide abstract]
ABSTRACT: To characterize a longitudinal relationship between highly active antiretroviral therapy immune recovery as defined by an increase in CD4 cell counts and any associated changes in intraocular pressure (IOP) in both patients with and patients without a history of cytomegalovirus (CMV) retinitis and to determine if human immunodeficiency (HIV)-induced reduction in IOP is reversible. Retrospective analysis of patient data collected from 1997 through 2004. Cohort of patients from one eye center, including patients from the Longitudinal Study of Ocular Complications of Acquired Immunodeficiency Syndrome. Linear regression analyses were conducted within the CMV and non-CMV groups to determine the change in IOP per 100-unit change in CD4 count. Average changes in IOP per change in CD4 count were compared between the CMV and the non-CMV groups using a Wilcoxon rank-sum test. Linear regression analyses were conducted within the CMV and non-CMV groups to determine the linear relationship between the 12-month change in IOP per 12-month 100-unit change in CD4 count. Intraocular pressure in relation to changes in CD4 cell counts. Compared with the non-CMV group, the median IOP change per change in CD4 count was not statistically different from the CMV group (0.9 vs. 1.7 mmHg/100 CD4 cells, respectively; P = 0.20). Analysis of the linear relationship between the 12-month change in IOP and the 12-month change in CD4 count within both the CMV and non-CMV groups showed a strong linear relationship: 67% of the variability in a 12-month IOP change for the CMV group (P<0.0001) and 36% of the variability in a 12-month IOP change for the non-CMV group (P<0.001). Reduction in T-lymphocyte count in HIV infection is accompanied by a decrease in IOP in both CMV-infected and non-CMV-infected eyes, and immune recovery is associated with an increase in IOP.Ophthalmology 03/2006; 113(3):451-5. · 5.45 Impact Factor -
Article: Implantation of an inactive epiretinal poly(dimethyl siloxane) electrode array in dogs.
[show abstract] [hide abstract]
ABSTRACT: The aim of this study is to investigate the long-term, mechanical biocompatibility of a polymer microtechnology that can be used to position electrodes in close proximity to the retina. Poly(dimethylsiloxane) (PDMS) arrays were manufactured by soft-lithography at Lawrence Livermore National Laboratory. The PDMS implant measured 4 mm x 40 mm x 55-60 microm and included 4-8 electrodes. Micromolded ribs were placed at the perimetry for strength and ease of manipulation. The PDMS arrays were implanted epiretinally in four normal dogs, with a single retinal tack used in each case to hold the device on the retina. The mechanical effects of the implant were followed up after surgical implantation by photography, fluorescein angiography, optical coherence tomography (OCT), and electrophysiologic tests. An intraoperative retinal tear occurred in the first implanted dog, causing retinal detachment and necessitating termination. The remaining dogs experienced no gross complications secondary to the array implantation procedure. During the follow-up period of 2 months in one eye and 6 months in three eyes, OCT demonstrated that the arrays were in close contact with the retina. Fluorescein angiography showed good perfusion of the retina under the array. At the end of 6 months, there was no statistical difference from baseline in mean retinal thickness under the array (P=0.43) or peripapillary retinal nerve fibre layer thickness corresponding to the implanted area (P=0.34). The mean distance between the array and the retinal surface varied from 32 to 68 microm throughout the follow-up. Histopathologic evaluation of the retinal implantation site in eyes followed for 6 months showed a general preservation of the normal, layered retinal structure, except for some localized retinal thinning in two eyes, where the array frame had been in direct retinal contact. The PDMS substrate micro array is a new and promising technology that can be scaled to support a high-density retinal stimulating array. Its implantation and handling is surgically manageable, and it forms a mechanically stable, acceptable interface with the inner retinal surface.Experimental Eye Research 02/2006; 82(1):81-90. · 3.26 Impact Factor -
Article: Intraoperative optical refractive biometry for intraocular lens power estimation without axial length and keratometry measurements.
[show abstract] [hide abstract]
ABSTRACT: To correlate intraoperative aphakic autorefraction to conventional emmetropic intraocular lens (IOL) calculations and derive an empiric predictive model for IOL estimation based on optical refractive biometry without axial length and keratometry measurements. Institutional Review Board of the University of Southern California, Los Angeles County General Hospital, Los Angeles, California, USA. A pilot group of 22 eyes of 22 patients scheduled for cataract surgery were enrolled in a prospective trial. All patients had a standard preoperative workup with subsequent cataract extraction and IOL implantation according to conventional biometric measurements and IOL calculations. Intraoperative autorefractive retinoscopy was used to obtain aphakic autorefraction and to measure the aphakic spherical equivalent before lens implantation. A linear regression analysis was used to correlate the aphakic spherical equivalent to the final adjusted emmetropic IOL power to empirically derive a refractive formula for IOL calculation (optical refractive biometry method). A second validation series of 16 eyes was used in a head-to-head comparison between the optical refractive biometry and the conventional IOL formulas. A subset of 6 eyes from the validation series were post-refractive cases having subsequent cataract surgery. Intraoperative retinoscopic autorefraction was successfully obtained in all 22 patients in the pilot group and all 16 patients in the validation group. The spherical equivalent of the aphakic autorefraction correlated linearly with the final adjusted emmetropic IOL power (P<.0001, with adjusted r(2)=.9985). The relationship was sustained over an axial length range of 21.43 to 25.25 mm and an IOL power range of 12.0 to 25.5 diopters (D). In a subsequent validation series of 10 standard and 6 post-laser in situ keratomileusis (LASIK) cataract cases, the optical refractive biometry method proved to be a better predictive model for IOL estimation than conventional formulas; 83% of the LASIK eyes and 100% of the normal eyes were within +/-1.0 D of the final IOL power when aphakic autorefraction was used, compared with 67% of LASIK eyes and 100% of the normal eyes, using the conventional methodology. A new model for IOL power calculation was derived based on an optical refractive methodology that breaks away from the conventional art introduced by Fyodorov in the 1960s. A purely refractive algorithm is used to predict the power of the IOL at the time of surgery without the need for axial length and keratometry measurements. This method bypasses some limitations of conventional biometry and shows promise in the post-refractive cataract cases.Journal of Cataract [?] Refractive Surgery 08/2005; 31(8):1530-6. · 2.26 Impact Factor -
Article: Experience with the baerveldt glaucoma implant in the management of pediatric glaucoma.
[show abstract] [hide abstract]
ABSTRACT: To report the clinical outcome in 48 eyes of 48 children who received a Baerveldt glaucoma implant (BGI) for the management of pediatric glaucoma. Retrospective, noncomparative case series. The medical records of all patients with pediatric glaucoma who underwent a BGI at two tertiary care referral centers in Los Angeles between 1990 and 1999 were reviewed. Intraocular pressure (IOP), intraoperative and postoperative complications, number of glaucoma medications, visual acuity, and pre- and postoperative corneal diameter and axial length were collected from patient records. Criteria for success were IOP between 6 and 21 mm Hg with or without glaucoma medications, no need for further glaucoma surgery, the absence of visually threatening complications, and some residual vision (minimum visual acuity of light perception). The study included 48 eyes from 48 patients aged 16 years and younger (mean age 4.1 years). Mean preoperative IOP was 31.2 +/- 25.7 mm Hg, and mean postoperative IOP was 16.4 +/- 4.9 mm Hg. Cumulative probability of success (based on the Kaplan-Meier survival curve) was 95% at 6 months, 90% at 1 year, 84% at 2 years, 74% at 36 months, and 58% at 48 months. On average, the BGIs were successful for a mean period of 5.6 years (67.7 months). Overall, 11 eyes failed, with the causes being uncontrolled IOP (eight eyes), retinal detachment (two eyes), and no light perception (one eye). Baerveldt glaucoma implants can be a safe and effective treatment modality for the management of pediatric glaucoma refractive to medical therapy.American Journal of Ophthalmology 06/2005; 139(5):847-54. · 4.22 Impact Factor -
Article: Long-term stimulation by active epiretinal implants in normal and RCD1 dogs.
[show abstract] [hide abstract]
ABSTRACT: An epiretinal prosthesis, consisting of an extraocular microelectronic stimulator and an intraocular electrode array, was implanted in one eye of three blind and three sighted dogs. Three dogs (2 blind, 1 normal) were stimulated for 120 days, and two dogs (both normal) for 60 and 103 days respectively for 8-10 h/day at levels of 0.1 mC cm(-2) and 0.05 mC cm(-2), with each stimulus level presented to half of the array. One blind dog was kept as an inactive implant control. During the study period, electroretinograms (ERG) and fundus photographs were recorded. At the end of the study period, the dogs were sacrificed and histological and morphometric evaluation was made of the retina. No inflammatory reaction, neovascularization or hemorrhage was observed during the follow-up examinations. ERGs were unchanged. Stimulus levels used were of sufficient amplitude to elicit cortical evoked potentials. Histological evaluation showed no inflammatory infiltrates or changes in retina morphometry related to electrical stimulation when compared to the unstimulated control eye. Morphometric analysis revealed no consistent differences relating to electrical stimulation. In summary, chronic electrical stimulation of the dog retina at up to 0.1 mC cm(-2) with an epiretinal prosthesis does not appear to adversely affect the retina.Journal of Neural Engineering 04/2005; 2(1):S65-73. · 3.84 Impact Factor -
Article: Ambient air pollution and atherosclerosis in Los Angeles.
[show abstract] [hide abstract]
ABSTRACT: Associations have been found between long-term exposure to ambient air pollution and cardiovascular morbidity and mortality. The contribution of air pollution to atherosclerosis that underlies many cardiovascular diseases has not been investigated. Animal data suggest that ambient particulate matter (PM) may contribute to atherogenesis. We used data on 798 participants from two clinical trials to investigate the association between atherosclerosis and long-term exposure to ambient PM up to 2.5 microm in aerodynamic diameter (PM2.5). Baseline data included assessment of the carotid intima-media thickness (CIMT), a measure of subclinical atherosclerosis. We geocoded subjects' residential areas to assign annual mean concentrations of ambient PM2.5. Exposure values were assigned from a PM2.5 surface derived from a geostatistical model. Individually assigned annual mean PM2.5 concentrations ranged from 5.2 to 26.9 microg/m3 (mean, 20.3). For a cross-sectional exposure contrast of 10 microg/m3 PM2.5, CIMT increased by 5.9% (95% confidence interval, 1-11%). Adjustment for age reduced the coefficients, but further adjustment for covariates indicated robust estimates in the range of 3.9-4.3% (p-values, 0.05-0.1). Among older subjects (greater than or equal to 60 years of age), women, never smokers, and those reporting lipid-lowering treatment at baseline, the associations of PM2.5 and CIMT were larger with the strongest associations in women 60 years of age (15.7%, 5.7-26.6%). These results represent the first epidemiologic evidence of an association between atherosclerosis and ambient air pollution. Given the leading role of cardiovascular disease as a cause of death and the large populations exposed to ambient PM2.5, these findings may be important and need further confirmation.Environmental Health Perspectives 03/2005; 113(2):201-6. · 7.04 Impact Factor -
Article: Race-ethnic differences in the extent, prevalence, and progression of coronary calcium.
[show abstract] [hide abstract]
ABSTRACT: To compare across four race-ethnic groups the baseline prevalence and extent of coronary calcium and the 7-year rate of progression in the extent of coronary calcium. The South Bay Heart Watch is a prospective cohort study designed to appraise the value of coronary calcium for predicting cardiovascular outcomes in asymptomatic adults with cardiac risk factors. Statistical analyses were conducted to evaluate ethnic differences in the prevalence, extent, and progression of coronary calcium among Caucasian, African-American, Hispanic, and Asian participants. Population-based study. Between December 1990 and December 1992, 1289 participants without coronary heart disease underwent baseline risk factor screening and computed tomography for coronary calcification (Cohort 1). Seven years later, 828 (64%) participants returned for follow-up evaluation and re-scanning (Cohort 2). Prevalence, extent, and progression of coronary artery calcium. In Cohort 2, compared to Whites, African Americans had a lower prevalence of coronary calcium at baseline (P=.012) and follow-up (P=.005), smaller calcium scores at baseline (P=.005) and follow-up (P=.0004), and less progression (P=.001); Hispanics had a lower prevalence of coronary calcium at follow-up (P=.04) with smaller calcium scores (P=.011), and less progression (P=.009). In contrast, no differences were seen between Whites and Asian/Pacific Islanders. Race-ethnic differences in progression persisted after adjusting for risk factors and participation bias (P<.05). The present results lend further credence to the notion that race-ethnic differences exist in the prevalence and rate of progression of coronary calcification. The relationship between calcification and the incidence of coronary heart disease in these race-ethnic groups needs further exploration.Ethnicity & disease 01/2005; 15(2):198-204. · 0.90 Impact Factor -
Article: Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines.
[show abstract] [hide abstract]
ABSTRACT: Tracking of coronary artery calcium (CAC) has been suggested for monitoring the effects of lipid control, but it is not known whether lipid control decreases progression of CAC. Seven hundred sixty-one subjects (mean age 64.5 +/- 7.3 years; 91% men; 69% positive for CAC) in an ongoing cohort study underwent baseline and follow-up (after 7.0 +/- 0.5 years) computed tomography for CAC. Subjects were stratified into low-risk (<2 risk factors), intermediate-risk (> or =2 risk factors but <20% risk of coronary heart disease over 10 years), or high-risk (> or =2 risk factors and >20% risk of coronary heart disease in 10 years or diabetes) groups. Lipid control was defined according to criteria of the National Cholesterol Education Program. Two-way analysis of covariance was used to examine the relation of low-density lipoprotein (LDL) cholesterol and risk group to change in CAC volume score. Control of levels of high-density lipoprotein (HDL) cholesterol and triglycerides was also examined in relation to progression of CAC. After adjustment for other risk factors and baseline CAC volume, CAC progression was similar between those with adequate and those with inadequate control of LDL cholesterol (p = 0.68) and across categories of optimal, intermediate, and higher risk LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/L [60 mg/dl]) were associated with less progression of CAC volume (151 vs 203 mm(3) in those with HDL cholesterol <1.0 mmol/L [40 mg/dl], p = 0.03). There was no relation between triglycerides and CAC progression (p = 0.54). Our findings do not support the use of CAC assessment for monitoring the control of LDL cholesterol, but greater progression of CAC may occur in those in whom HDL cholesterol is not controlled.The American Journal of Cardiology 09/2004; 94(4):431-6. · 3.37 Impact Factor -
Article: Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis.
[show abstract] [hide abstract]
ABSTRACT: To evaluate the effect of viral IL-10 on the lacrimal gland immunopathologic response in the ocular surface disease, induced autoimmune dacryoadenitis. Disease was induced in rabbits by injecting inferior lacrimal glands with peripheral blood lymphocytes activated by 5 days of coculture with autologous acinar cells in a mixed-cell reaction. In the treated group, an adenoviral vector carrying the vIL-10 gene was concurrently injected with activated lymphocytes. Tears were collected periodically for quantitation of IL-10 by ELISA. Two weeks after disease induction, tear production, tear film breakup time, and rose bengal staining score were determined. Sectioned glands were immunostained for expression of CD4, CD8, rabbit thymic lymphocyte antigen (RTLA), CD18 and major histocompatibility complex class II. The titer of vIL-10 in tears was at its maximum on day 3, started to decline by day 7, and was undetectable by day 14. In the diseased group, the tear production rate and tear film breakup time were significantly decreased, and rose bengal staining was significantly increased. Diseased glands had immune cell infiltrates containing CD4+, RTLA+, and CD18+ cells, and major histocompatibility complex class II expression was increased. These changes were significantly ameliorated by expression of vIL-10. In vivo transduction of the lacrimal gland with AdvIL-10 resulted in the transient appearance of vIL-10 in tears. The presence of vIL-10 partially suppressed the appearance of Sjögren-syndrome-like features of reduced tear production, accelerated tear breakup, ocular surface disease, and immunopathologic response. Anti-inflammatory cytokine gene expression may offer a therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable vectors become available.Investigative Ophthalmology & Visual Science 06/2004; 45(5):1375-81. · 3.60 Impact Factor -
Article: Valganciclovir therapy for immune recovery uveitis complicated by macular edema.
[show abstract] [hide abstract]
ABSTRACT: To determine whether treatment with valganciclovir will improve visual acuity in eyes with immune recovery uveitis complicated by macular edema. Prospective open label controlled Phase II drug study. Five patients with chronic macular edema as a result of immune recovery uveitis were studied. Baseline fluorescein angiograms, best-corrected ETDRS visions, and cytomegalovirus (CMV) lymphoproliferative T-cell function assays were obtained and repeated after three months of valganciclovir therapy (900 mg daily) and again three months after withdrawal of therapy. Vision improved by a mean of 11 letters in the treatment phase (P =.05). Graded angiograms showed three patients had treatment reduction of macular edema. One patient had rebound increase in macular edema after the withdrawal phase. The CMV lymphoproliferative response was not affected by the valganciclovir. Results suggest valganciclovir treatment may benefit visual acuity in patients with macular edema from immune recovery uveitis.American Journal of Ophthalmology 05/2004; 137(4):636-8. · 4.22 Impact Factor -
Article: Comparison of calcium scores from thick- and thin image slice-computed tomography scanning in predicting future coronary events.
[show abstract] [hide abstract]
ABSTRACT: Computed tomographic image slices between 2.5 and 3.0 mm are commonly used for coronary calcium scanning. To evaluate the comparative accuracy of thicker image slices (5 to 6 mm) for predicting coronary events, we acquired both types of scans in 280 research participants and clinically followed them up for 7 years. We found that thick-slice image scanning and image assessment ranked calcium scores similarly and that measurements from both scanning methods predicted coronary heart disease events equally.The American Journal of Cardiology 04/2004; 93(5):624-6. · 3.37 Impact Factor -
Article: Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy.
[show abstract] [hide abstract]
ABSTRACT: To evaluate the expression of connective tissue growth factor (CTGF) and its fragments in the vitreous of patients with proliferative diabetic retinopathy (PDR) and to localize CTGF expression in associated preretinal membranes. Vitreous was obtained from 24 patients with active PDR, 4 patients with quiescent PDR, and 23 patients with other retinal diseases and no diabetes, including 5 patients with vitreous hemorrhage. Enzyme-linked immunosorbent assay was used to determine levels of whole CTGF and its NH2- and COOH-terminal fragments. Preretinal membranes from three patients with active PDR were stained immunohistochemically for the presence of CTGF and cell type-specific markers. A significant increase in NH2-terminal CTGF fragment content was found in vitreous samples from patients with active PDR when compared with samples from nondiabetic patients (P<0.0001) or patients with quiescent PDR (P=0.02). Levels of NH2-terminal CTGF were also greater in vitreous samples from diabetic patients with vitreous hemorrhage compared with samples from nondiabetic patients with vitreous hemorrhage (P=0.02). Vitreous levels of whole CTGF were similar in all groups. COOH-terminal fragments of CTGF were not detected. CTGF immunoreactivity was predominantly localized to smooth muscle actin-positive myofibroblasts within active PDR membranes. -NH2-terminal CTGF fragment content is increased in the vitreous of patients with active PDR, suggesting that it plays a pathogenic role or represents a surrogate marker of CTGF activity in the disorder. The localization of CTGF in myofibroblasts suggests a local paracrine mechanism for induction of fibrosis and neovascularization.Diabetes Care 04/2004; 27(3):758-64. · 8.09 Impact Factor -
Article: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals.
[show abstract] [hide abstract]
ABSTRACT: Guidelines advise that all adults undergo coronary heart disease (CHD) risk assessment to guide preventive treatment intensity. Although the Framingham Risk Score (FRS) is often recommended for this, it has been suggested that risk assessment may be improved by additional tests such as coronary artery calcium scoring (CACS). To determine whether CACS assessment combined with FRS in asymptomatic adults provides prognostic information superior to either method alone and whether the combined approach can more accurately guide primary preventive strategies in patients with CHD risk factors. Prospective observational population-based study, of 1461 asymptomatic adults with coronary risk factors. Participants with at least 1 coronary risk factor (>45 years) underwent computed tomography (CT) examination, were screened between 1990-1992, were contacted yearly for up to 8.5 years after CT scan, and were assessed for CHD. This analysis included 1312 participants with CACS results; excluded were 269 participants with diabetes and 14 participants with either missing data or had a coronary event before CACS was performed. Nonfatal myocardial infarction (MI) or CHD death. During a median of 7.0 years of follow-up, 84 patients experienced MI or CHD death; 70 patients died of any cause. There were 291 (28%) participants with an FRS of more than 20% and 221 (21%) with a CACS of more than 300. Compared with an FRS of less than 10%, an FRS of more than 20% predicted the risk of MI or CHD death (hazard ratio [HR], 14.3; 95% confidence interval [CI]; 2.0-104; P =.009). Compared with a CACS of zero, a CACS of more than 300 was predictive (HR, 3.9; 95% CI, 2.1-7.3; P<.001). Across categories of FRS, CACS was predictive of risk among patients with an FRS higher than 10% (P<.001) but not with an FRS less than 10%. These data support the hypothesis that high CACS can modify predicted risk obtained from FRS alone, especially among patients in the intermediate-risk category in whom clinical decision making is most uncertain.JAMA The Journal of the American Medical Association 01/2004; 291(2):210-5. · 30.03 Impact Factor -
Article: Correcting the corneal power measurements for intraocular lens power calculations after myopic laser in situ keratomileusis.
[show abstract] [hide abstract]
ABSTRACT: To describe and evaluate a refraction-derived method and a clinically derived method to calculate the correct corneal power for intraocular lens (IOL) power calculations after laser in situ keratomileusis (LASIK) and to compare the results to the commonly used history-derived method. Interventional case series. Retrospective analysis of consecutive cases from clinical practice. Two hundred randomly selected eyes from 200 patients were evaluated before and after LASIK surgery. For each patient, we established the pre-LASIK and post-LASIK spectacle refraction, the pre-LASIK (Kpre) and post-LASIK K readings (Kpost). We then calculated for each case the pre- and post-LASIK refraction at the corneal plane and the amount of correction obtained by the refractive surgery (CRc). The cases were divided into two groups. Group I was used to derive the two formulas. The K values were calculated using the history-derived method (Kc.hd) in which Kc.hd = Kpre - CRc. Kc.hd was compared with Kpost. The average difference was 0.23 diopters for every diopter of myopia corrected. This value was used to calculate the corneal power using the refraction-derived method (Kc.rd) where Kc.rd = Kpost -0.23CRc. A regression equation was used to develop a clinically derived method (Kc.cd) where Kc.cd = 1.14Kpost -6.8. The values obtained with the two methods were compared with the Kc.hd values in group II to validate the results. Both Kc.rd and Kc.cd values correlated highly with Kc.hd when plotted on a scattergram (P <.001), and there was no statistically significant difference between the mean keratometric values (P >.5). The corneal power measurements for intraocular lens power calculations after LASIK need to be corrected to avoid hypermetropia after cataract surgery by either the history-derived method, the refraction-derived method, or the clinically derived method.American Journal of Ophthalmology 10/2003; 136(3):426-32. · 4.22 Impact Factor -
Article: Sweep visual evoked potential evaluation of contrast sensitivity in Alzheimer's dementia.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to evaluate primary afferent visual pathway function by objectively testing contrast sensitivity in persons with Alzheimer's dementia (AD), using a sweep visual evoked potential technique. Twenty-five patients, 16 with AD and 9 elderly control (EC) subjects, were enrolled from the University of Southern California Rancho Los Amigos Medical Center. The patients with AD had clinical dementia ratings ranging from 0.5 to 3, corresponding to mild to moderate disease. All participants underwent refraction and screening for ophthalmic disease. Subjects were evaluated with the sweep visual evoked potential technique. Each trial consisted of logarithmically increasing contrast over a 10-second period. Subjects were evaluated monocularly at spatial frequencies of 1, 5, and 8 cyc/deg. Patients were not required to integrate and respond to stimuli. Mean contrast sensitivity thresholds were significantly higher in patients with AD than in EC subjects. The mean contrast sensitivities in the AD group were 4.0%, 9.6%, and 18.6%, at 1, 5, and 8 cyc/deg, respectively. The corresponding sensitivities in the EC group were 2.1%, 5.3%, and 11.4%, at 1, 5, and 8 cyc/deg, respectively. These threshold differences were significant at probabilities of 0.01, 0.05, and 0.07. There was no correlation between clinical dementia ratings and reduction of contrast sensitivity thresholds. Confounding factors such as age, gender, nuclear sclerosis, and visual acuity were evaluated. Visual acuity was the only factor significantly different between AD responders and AD nonresponders at 1 and 5 cyc/deg. These results suggest patients with AD have deficits in contrast sensitivity attributable to dysfunction of the primary afferent visual pathway.Investigative Ophthalmology & Visual Science 03/2003; 44(2):875-8. · 3.60 Impact Factor -
Article: Intraocular pressure control and complications with two-stage insertion of the Baerveldt implant.
[show abstract] [hide abstract]
ABSTRACT: To evaluate intraocular pressure (IOP) control and the prevalence of complications associated with the two-stage insertion of the Baerveldt implant. Retrospective, noncomparative, interventional case series. We reviewed the medical records of all patients who underwent the two-stage Baerveldt implantation for advanced glaucoma between January 1995 and November 1998 at the Doheny Eye Institute, Los Angeles, California. All eyes with a minimum of 6 months of follow-up were included in the study. Eyes that failed before 6 months after stage II were also included in the study. The criterion for surgical success was postoperative IOP of 6 mmHg or more and 21 mmHg or less on two or more consecutive measurements with or without the use of glaucoma medications and without loss of light perception or further surgical intervention to lower IOP. Nineteen eyes from 19 patients were included. Median postoperative follow-up was 17 months (range, 3-56 months). The cumulative probability of success was 89% at both 12 and 24 months. The median preoperative IOP of 21 mmHg (range, 12-33 mmHg) was reduced to a median postoperative IOP of 12 mmHg (range, 1-17 mmHg; P < 0.0001). The median number of glaucoma medications before surgery was three and after surgery was one (P < 0.0001). Visual acuity remained the same or improved in 13 eyes (68%). One eye experienced hypotony (5%), and in two eyes (11%) suprachoroidal hemorrhages developed. The two-stage insertion of the Baerveldt implant effectively reduced IOP, produced few complications, and preserved visual acuity in more than two thirds of eyes with advanced glaucomatous damage.Ophthalmology 02/2003; 110(2):353-8. · 5.45 Impact Factor -
Article: Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals.
[show abstract] [hide abstract]
ABSTRACT: The South Bay Heart Watch is a prospective cohort study designed to appraise the value of coronary calcium and risk factors for predicting outcomes in asymptomatic adults. Two factors that may be related to subsequent cardiovascular events are coronary calcium (CAC, a manifestation of subclinical atherosclerosis) and high-sensitivity C-reactive protein (CRP, a measure of chronic inflammation). Between December 1990 and December 1992, 1461 participants without coronary heart disease underwent baseline risk factor screening, computed tomography for CAC, and measurement of CRP. Participants were followed up for 6.4+/-1.3 years. Cox regression analyses were conducted for the 967 nondiabetics with CRP levels < or =10 mg/L to estimate the risk-factor-adjusted relative risks of CAC and CRP for the occurrence of (1) nonfatal myocardial infarction (MI) or coronary death and (2) any cardiovascular event (MI, coronary death, coronary revascularization, or stroke). CAC was a predictor of both end points (P<0.005), and CRP was a predictor of any cardiovascular event (P=0.03). Risk group analysis defined by tertiles for CAC (<3.7, 3.7 to 142.1, >142.1) and the 75th percentile for CRP (>4.05 mg/L) indicated that there was increasing risk with increasing calcium and CRP. Relative risks for the medium-calcium/low-CRP risk group to high-calcium/high-CRP risk group ranged from 1.8 to 6.1 for MI/coronary death (P=0.003) and 2.8 to 7.5 for any cardiovascular event (P<0.001). Participants without diabetes and those at intermediate risk may benefit from risk stratification based on high-sensitivity CRP levels and CAC, because both factors contribute independently toward the incidence of cardiovascular events.Circulation 10/2002; 106(16):2073-7. · 14.74 Impact Factor
Top co-authors
Top Journals
Institutions
-
2006
-
University of California, San Diego
- Department of Ophthalmology
San Diego, CA, USA
-
-
1995–2006
-
University of Southern California
- • Doheny Eye Institute
- • Department of Ophthalmology
Los Angeles, CA, USA
-
-
2005
-
University of California, Los Angeles
- Department of Ophthalmology
Los Angeles, CA, USA
-
